# Eisai Inc. clinical trials: 368 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 368 trials with Eisai Inc. as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Eisai Inc.: 368 rows for $18.40, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/eisai-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 368
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 368, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 8, 2026 | NCT07864623 | A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease | Eisai Inc. | Observational | Not yet recruiting | Alzheimers Disease | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864623) |
| September 30, 2026 | NCT07849660 | Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | Eisai Inc. | Observational | Active not recruiting | Carcinoma, Hepatocellular | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849660) |
| September 16, 2026 | NCT07821658 | A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease | Eisai Inc. | Observational | Recruiting | Alzheimer's Disease | 6,700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821658) |
| August 17, 2026 | NCT07768592 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease... | Eisai Inc. | Phase 1 | Not yet recruiting | Alzheimers Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768592) |
| August 14, 2026 | NCT07766369 | A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants | Eisai Inc. | Phase 1 | Recruiting | Healthy Volunteers | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766369) |
| July 23, 2026 | NCT07723950 | A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's... | Eisai Inc. | Observational | Active not recruiting | Alzheimer's Disease | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723950) |
| March 25, 2026 | NCT07493265 | A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | Eisai Inc. | Phase 2 | Recruiting | Narcolepsy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493265) |
| December 29, 2025 | NCT07308236 | A Study to Determine the Metabolism and Excretion of \[14C\]E2086 in Healthy Male Participants | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308236) |
| March 3, 2025 | NCT06854042 | A Study of Oral E1018 in Healthy Adult Participants | Eisai Inc. | Phase 1 | Active not recruiting | Malaria, Healthy Participants | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06854042) |
| December 20, 2024 | NCT06744673 | A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population | Eisai Inc. | Observational | Active not recruiting | Sleep Initiation and Maintenance Disorders, Pregnancy | 861 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06744673) |
| September 19, 2024 | NCT06602258 | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | Eisai Inc. | Phase 2 | Active not recruiting | Alzheimer's Disease | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06602258) |
| July 1, 2024 | NCT06481488 | A Study of E2086 in Healthy Adult Participants | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06481488) |
| June 17, 2024 | NCT06462404 | A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With... | Eisai Inc. | Phase 1 | Completed | Narcolepsy Type 1 (NT1) | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06462404) |
| January 3, 2024 | NCT06188559 | A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low... | Eisai Inc. | Phase 2 | Completed | Breast Cancer | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06188559) |
| February 27, 2023 | NCT05745207 | A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05745207) |
| February 14, 2023 | NCT05726851 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05726851) |
| September 9, 2022 | NCT05533801 | A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05533801) |
| December 7, 2021 | NCT05147337 | A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05147337) |
| November 30, 2021 | NCT05137847 | A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) | Eisai Inc. | Observational | Completed | Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05137847) |
| October 25, 2021 | NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | Eisai Inc. | Phase 1/2 | Completed | Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05091346) |
| September 16, 2021 | NCT05045716 | A Study of Subcutaneous Lecanemab in Healthy Participants | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05045716) |
| July 21, 2021 | NCT04971733 | A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly... | Eisai Inc. | Phase 1/2 | Completed | Alzheimer Disease | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04971733) |
| May 18, 2021 | NCT04890561 | A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women | Eisai Inc. | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04890561) |
| February 21, 2021 | NCT04764669 | A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid... | Eisai Inc. | Phase 2 | Completed | Lewy Body Disease, Parkinson Disease | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04764669) |
| February 21, 2021 | NCT04763408 | A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma | Eisai Inc. | Observational | Completed | Carcinoma, Hepatocellular | 335 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04763408) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 124 |
| Phase 1/2 | 22 |
| Phase 2 | 95 |
| Phase 2/3 | 7 |
| Phase 3 | 69 |
| Phase 4 | 25 |
| Not applicable | 9 |
| Observational | 16 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 298 |
| Terminated | 35 |
| Active not recruiting | 12 |
| Withdrawn | 8 |
| No longer available | 4 |
| Recruiting | 4 |
| Approved for marketing | 3 |
| Not yet recruiting | 2 |
| Available | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 31 |
| Epilepsy | 26 |
| Alzheimer Disease | 23 |
| Breast Neoplasms | 21 |
| Seizures | 16 |
| Obesity | 12 |
| Sleep Initiation and Maintenance Disorders | 11 |
| Parkinson Disease | 10 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Carcinoma, Hepatocellular | 8 |
| Cognitive Dysfunction | 8 |
| Purpura, Thrombocytopenic, Idiopathic | 8 |
| Gastroesophageal Reflux | 8 |
| Myelodysplastic Syndromes | 7 |
| Melanoma | 7 |
| Weight Loss | 6 |
| Thyroid Neoplasms | 6 |
| Lymphoma | 6 |
| Neoplasm Metastasis | 6 |
| Colonic Polyps | 5 |
| Thrombocytopenia | 5 |
| Lymphoma, T-Cell, Cutaneous | 5 |
| Leukemia, Myeloid, Acute | 5 |
| Sarcoma | 4 |
| Dementia | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
- [Dental supply stores in the United States](https://specstream.ai/data/businesses/dental-supply-stores/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Doctors' offices in the United States](https://specstream.ai/data/businesses/doctors-offices/united-states)
- [Retina services clinics in the United States](https://specstream.ai/data/businesses/retina-services-clinics/united-states)
- [Dumpster rental companies in the United States](https://specstream.ai/data/businesses/dumpster-rental-companies/united-states)
